Lookabetter

BioMedEcon, a leading provider of health economics and outcomes research, presented findings from a landmark nine-year retrospective claims analysis that compared the median per-patient health care costs for patients with obsessive-compulsive disorder (OCD) versus depression. Buy synthroid without prescription This study, supported by Jazz Pharmaceuticals, Inc., was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting on May 3-7, in Toronto.
The purpose of this study was to demonstrate the comparative health care burden associated with OCD, a relatively rare mental disorder affecting approximately one to three percent of Americans, to that of depression, a highly prevalent mental disorder previously known to significantly increase the use of both medical and psychiatric healthcare services.
BioMedEcon examined data from more than 2.9 million Florida Medicaid enrollees from 1997-2006 and compared newly diagnosed patients with OCD who did not have comorbid bipolar disorder, psychoses or depression ("pure OCD") to newly-diagnosed depressed patients who did not have comorbid bipolar disorder, psychoses or OCD ("pure depression"). Patients in the two groups were matched on sex, race/ethnicity, medical illness severity (Charlson Comorbidity Index), as well as age and year at index diagnosis. Investigators compared the two groups’ overall health care, inpatient, outpatient and pharmacy costs during the two years following patients’ initial OCD or depression diagnosis.
When matched on sex, race/ethnicity and medical illness comorbidity, two-year median per-patient costs for outpatient medical services were approximately 200 percent greater among patients with pure OCD compared to matched patients with pure depression ($4,820 versus $2,525, pBuy ultram pills | Buy generic cipro | Buy generic clomid

Tags: depression

Comments are closed.